Translating Proteomics

Nautilus Biotechnology
  • 5.0 (6)
  • LIFE SCIENCES
Translating Proteomics

‘Translating Proteomics’ explores the science of proteomics and its growing impact on biological research, biomarker discovery, drug development, food and energy security, and a range of other timely topics. Hosts Parag Mallick Ph.D. and Andreas Huhmer Ph.D. of Nautilus Biotechnology aim to share their perspectives on important issues in proteomics, deepen your love of science, and prompt you to question assumptions about what may be possible.

  1. 2024 Year-End Special: 3 Exciting Examples of Proteomics Research

    3 DAYS AGO

    2024 Year-End Special: 3 Exciting Examples of Proteomics Research

    On this special, year-end episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer discuss three of their favorite proteomics publications from 2024. They'll cover one paper in each of the following topic areas: Proteomics in pre-clinical researchProteomics in basic researchTechnology development in proteomics Synopses of each of the papers can be found below and you can find many more insights in the podcast. Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomicsIn this work from Professor Bernhard Kuster’s Lab at the Technical University of Munich, researchers assess protein abundance changes that result from treating Jurkat acute T cell leukemia cells with 144 drugs over five drug doses. The researchers use their proteomic data to generate millions of dose response curves for the thousands of proteins measured and discover that the drugs impact many more proteins and pathways than those identified as drug targets. In addition, they checked how 7 of the drug treatments impacted the transcriptome and found there was often discordance between impacts at the mRNA level and the protein level. This works highlights the many ways drugs can impact biological systems and suggests that similar studies will help researchers understand the effects of drug treatments and may even aid in the development of more effective or more specific therapies. Find the publication here. Natural proteome diversity links aneuploidy tolerance to protein turnoverAs we discussed on a previous episode of Translating Proteomics, genome alterations often fail to faithfully propagate to the proteome. In this work, researchers from the labs of Professor Judith Berman at Tel Aviv University and Professor Markus Ralser at the Charité - Universitätsmedizin Berlin, investigate the means through which yeast strains adapt to chromosome gains or losses (aneuploidy). They assess the concordance between changes in mRNA and protein expression in aneuploid yeast that were either found in nature or generated in the lab. The researchers observed dosage compensation, a tendency to return to expression levels associated with normal chromosome numbers, for both mRNAs and proteins expressed on aneuploid chromosomes. However, dosage compensation was much stronger at the protein level than the mRNA level and even stronger at the protein level in naturally aneuploid strains compared to lab-generated strains. This work suggests that multiomics efforts are necessary to determine the effects of genomic alterations. In addition, the authors find that protein degradation, as observed through increased ubiquitination, increased turnover of proteins encoded in aneuploid chromosomes, and the up regulation of the proteasome complex, is a key means of dosage compensation. Finally, because the naturally aneuploid strains achieved a higher level of dosage compensation than the lab-generated strains, the authors suggest there has been selection for natural aneuploid strains that down-regulate proteins causing detrimental effects. a...

    52 min
  2. AI and Biotech - The Promise and the Pitfalls with Matt McIlwain and Vijay Pande

    DEC 4

    AI and Biotech - The Promise and the Pitfalls with Matt McIlwain and Vijay Pande

    Parag Mallick discusses the role of AI and machine learning in biotech with special guests Vijay Pande from Andreessen Horowitz and Matt McIlwain from Madrona Venture Group. Their fascinating conversation covers: Advances that have enabled biotech to make use of AI and machine learningHow founders are applying AI and machine learning in biotechThe future of AI and machine learning in biotech Chapters 00:00 - Introduction 04:37 - How did Vijay and Matt get into AI and ML 07:33 - The importance of structured data, advances in compute, and algorithmic advances in driving the boom in machine learning 18:44 - The Intersection of AI and biology 21:57 - The evolution of biological models 31:55 - The Complexity of biological data 39:42 - Ways founders and biotech startups are using AI 43:25 - Favorite/Impactful applications of AI/ML 47:00 - AI for experimental design 50:13 - The future of AI in bio/health Resources Learn more about Matt McIlwainLearn more about Vijay PandeFolding at HomeLearn about various types of machine learning on IBM's websiteLearn about autoencoders on IBM's websiteLearn more about transformers on NVIDIA's blogTranslating Proteomics Episode 6 - The Future of AI in Biomedicine

    54 min
  3. A New Era In Alzheimer's Research with Sarah DeVos

    OCT 30

    A New Era In Alzheimer's Research with Sarah DeVos

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer’s research with special guest and Curie Bio Drug Maker in Residence, Sarah DeVos Ph.D. Their conversation focuses on: The impact of molecular diagnostics on Alzheimer’s researchRecent Alzheimer’s drug approvalsThe future of Alzheimer’s research *Small edit on Sarah's background - She did her graduate work at Washington University in St. Louis and a Postdoc at Massachusetts General Hospital* Chapters00:00 – Introduction 01:54 – Why Sarah began studying Alzheimer’s 03:39 – Current tools and needs for future Alzheimer’s diagnostics 09:52 – Recent drug approvals in the Alzheimer’s space and their relationship to diagnostics 14:26 – Is it possible to develop biomarkers that detect Alzheimer’s at its earliest stages? 16:36 – What is limiting the development of new Alzheimer’s biomarkers? 17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer’s 19:33 – The genetics of Alzheimer’s 22:19 – Novel approaches to identifying and understanding Alzheimer’s pathology  25:54 – Where can proteomics advance Alzheimer’s research? 31:25 – The role of proteomics in Alzheimer’s animal models 34:33 – Sarah’s hopes for the next 10 years of Alzheimer’s research 41:39 - Outro ResourcesDominant Inherited Alzheimer’s Network (DIAN) trials research updates o   In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer’s disease. Amyloid plaque reducing clinical trials: o   Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease (Haeberlein et al. 2022) o   Donanemab in Early Symptomatic Alzheimer Disease - The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023) o   Lecanemab in Early Alzheimer’s Disease (Van Duck et al. 2022) Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024) o   Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer’s disease Resurrecting the Mysteries of Big Tau (Fischer and Baas 2021) o   Review covering a potentially neuro-protective form of tau called “Big tau” Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience...

    42 min
  4. Plasma Proteomics - The Dream and the Nightmare

    OCT 28

    Plasma Proteomics - The Dream and the Nightmare

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! On this episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss the challenges and opportunities of plasma proteomics. Their conversation focuses on: ·      Why blood plasma may be a good source of protein biomarkers ·      Current methodologies and pitfalls in plasma proteomics ·      The path forward for plasma proteomics What is Plasma Proteomics?For those who are new to this topic, plasma is the liquid portion of the blood distinct from fractions containing red and white blood cells. Given the relatively non-invasive ways physicians can collect patient plasma, and the blood’s intimate association with tissues throughout the body, plasma is potentially an excellent source of protein biomarkers. Yet, it is quite difficult to measure the levels of all plasma proteins because their concentrations span over 12 orders of magnitude. This episode features an in-depth discussion of the ways plasma proteomics efforts have and have not lived up to the promise of biomarker discovery and what we can do to advance plasma biomarker discovery efforts in the future. Chapters00:00 – 01:01 – Intro 01:02 – 4:55 – What is the promise of plasma proteomics? 04:55  – 07:23 – Is the plasma proteome really the best source of biomarkers? 07:23 – 10:16 – How do proteins get into the blood and what are the implications for biomarker discovery? 10:16 – 13:59 – Is it clear that proteins are the best candidates for blood biomarkers? 13:59 – 19:57 – Advances in and the future of comprehensive plasma proteomics 19:57 – 22:31 – Pros and cons of fractionating the plasma proteome to discover biomarkers 22:31 – 28:14 – Progress in identifying multiomic plasma biomarkers and the path forward 28:14 – End – Outro ResourcesNano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome (Gardner et al. 2022) o   Review from focused on the development multiomics liquid biopsies Multicompartment modeling of protein shedding kinetics during vascularized tumor growth (Machiraju et al. 2020) o   Work from Parag’s Lab investigating tumor protein shedding Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor (Frieboes et al. 2015) o   Tumor protein shedding work from Parag’s Lab Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations (Hori and Gambhir et al. 2011) o   Study modeling how much protein could be shed and detected from different size tumors a href="https://pubmed.ncbi.nlm.nih.gov/12488461/" rel="noopener noreferrer"...

    29 min
  5. Protein Function 201 with Kathryn Lilley

    OCT 17

    Protein Function 201 with Kathryn Lilley

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! Proteins adopt a wide variety of functions depending upon factors like their location in the cell, their modifications, and the biomolecules they interact with. While many of us may have been taught that single genes produce single proteins that have single functions, protein function is far more dynamic than that. In this episode of Translating Proteomics, Nautilus Co-Founder and Chief Scientist Parag Mallick sits down with University of Cambridge Professor and proteomics expert Kathryn Lilley to discuss our evolving understanding of protein function. They cover: How they came to realize protein function is more complex than one gene, one enzyme, one functionFactors that give rise to the dynamic complexity of protein function including proteoforms, protein localization, and moonlightingSteps we can take to better understand and teach others about the complexities of protein function Research diving into the complexities of protein functionResearch from the Beltrao Lab using bioinformatics techniques to identify functional phosphosites (Ochoa et al. 2020)Work from the Lilley Lab integrating techniques to investigate ome-wide localization of both RNA and protein (Villanueva et al. 2024)Lilley Lab preprint investigated protein localization changes in a cancer cell line as a result of ionizing radiation treatment (Christopher et al. 2024).Collaborative work with the Lundberg Lab mapping subcellular proteomics (Thul et al. 2017). Additional protein function resourcesMoonProt - A database for moonlight proteins from Professor Constance Jeffrey's LabTranslating Proteomics Episode 5 - Why the Biology Surrounding Biology's Central Dogma is Wrong

    46 min
  6. Are Proteins A Myth? With Special Guest Professor Neil Kelleher

    OCT 3

    Are Proteins A Myth? With Special Guest Professor Neil Kelleher

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! In our Translating Proteomics episode titled "Harnessing Proteoforms to Understand Life's Complexity", Parag and Andreas discussed why proteoforms are important in a theoretical sense. In this episode, Parag sits down with Northwestern University Professor and proteoform pioneer, Neil Kelleher to dive deep into the biology of proteoforms. They cover: What proteoforms areExamples of the importance of proteoformsThe scale of and technological advances needed to meet the challenges of proteoform biology. Some examples of the power of proteoforms covered in this episodeRecent work from Neil's lab showing blood proteoforms can help predict liver transplant success (Melani et al. 2022).Work form Ying Ge's lab showing changes in troponin proteoforms correlate with varying degrees of heart disease (Zhang et al. 2011).The BioTyper - a mass spectrometry-based device that can identify different kinds of microbes. Additional proteoform resourcesThe Human Proteoform Atlas webpagePublication describing The Human Proteoform Atlas (Hollas et al. 2022)Publication discussing how many human proteoforms there are (Aebersold et al. 2018)Animation - Proteoform Analysis on the Nautilus Proteome Analysis Platform

    48 min

  7. JUN 26

    Expanding the Druggable Universe with Proteomics

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! Despite incredible leaps in our understanding of molecular biology, the majority of drug development efforts still fail, and those that succeed often fail to return investment dollars. Proteomics has the potential to change that by providing high-resolution views of the biochemical drivers of biological function - proteins. In this episode of Translating Proteomics, Parag and Andreas discuss how proteomics can help researchers identify good drug targets, personalize drug development, and advance precision medicine. Chapters: 00:00 - How do we define good drug targets and "druggable" in the age of proteomics 08:16 - Advancing personalized medicine through proteomics 10:58 - How proteomics technologies have changed drug development 15:13 - New abilities next-generation proteomics technologies give us in drug development Learn about proteomics and biomarker discovery: https://youtu.be/8rcAxHSRGYs?si=kZ0UX42TJ8tWIaSN Learn more about proteomics and precision medicine: https://youtu.be/bzRlM45agBY?si=eop2XcGLc_oLeiVc

    26 min

  8. JUN 19

    Harnessing Proteoforms to Understand Life's Complexity

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! Proteins are far more than just the output of genes. They can be modified in myriad ways to produce millions of proteoforms with altered dynamics, localization, and function. For a comprehensive understanding of biology that will propel drug development and biomarker discovery forward, we need to be able to measure proteoforms routinely. In this episode, Parag and Andreas discuss the incredible value that will come from studying proteoforms and describe what it will take to make proteoform measurement a routine part of biology research. Chapters: 00:00 - Introduction to proteoforms 09:38 - Evidence that proteoforms are important and how we can use proteoform data 19:28 - Technology advances needed to understand proteoform biology

    25 min
See All (14)

Ratings & Reviews

5
out of 5
6 Ratings

About

‘Translating Proteomics’ explores the science of proteomics and its growing impact on biological research, biomarker discovery, drug development, food and energy security, and a range of other timely topics. Hosts Parag Mallick Ph.D. and Andreas Huhmer Ph.D. of Nautilus Biotechnology aim to share their perspectives on important issues in proteomics, deepen your love of science, and prompt you to question assumptions about what may be possible.

Information

  • Creator
    Nautilus Biotechnology
  • Years Active
    2K
  • Episodes
    14
  • Rating
    Clean
  • Copyright
    © Copyright 2024 Nautilus Biotechnology
  • Show Website
    Translating Proteomics

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada